药格局 YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
2026/08/18 – 2026/08/24
- New acceptances this week
- 458
- Drugs with new generic filings (by drug name, de-duplicated)
- 54
- Accepted this week, now under review
- 305
DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.
Drug and company names link to detail pages; sign in to view them.
New acceptances this week
By application type and drug type
458filings, 77 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 242 |
| Generic | 77 |
| New drug | 68 |
| Import | 49 |
| Unspecified | 14 |
| Import re-registration | 8 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 230 |
| TCM | 136 |
| 治疗用生物制品 | 78 |
| 预防用生物制品 | 12 |
| Biologic | 2 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
54 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | 非布司他片 | 4 | 2 | 15 |
| 2 | 硫酸氨基葡萄糖胶囊 | 3 | 3 | 50 |
| 3 | 布立西坦片 | 3 | 1 | 16 |
| 4 | 吡非尼酮片 | 2 | 2 | 5 |
| 5 | 氧（液态） | 2 | 2 | 14 |
| 6 | 注射用盐酸兰地洛尔 | 2 | 2 | 19 |
| 7 | 生理氯化钠溶液 | 2 | 2 | 17 |
| 8 | 艾拉莫德片 | 2 | 2 | 24 |
| 9 | 艾普拉唑肠溶片 | 2 | 2 | 26 |
| 10 | 阿司匹林肠溶片 | 2 | 2 | 10 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
261 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | 吉林高邈药业股份有限公司 | 23 | 19 | 0 |
| 2 | 江苏恒瑞医药股份有限公司 | 10 | 3 | 0 |
| 3 | Eli Lilly and Company | 8 | 2 | 0 |
| 4 | 吉林道君药业股份有限公司 | 7 | 7 | 0 |
| 5 | AstraZeneca AB | 7 | 4 | 0 |
| 6 | Pfizer Inc. | 7 | 4 | 0 |
| 7 | Novo Nordisk A/S | 7 | 1 | 0 |
| 8 | 北京同仁堂科技发展股份有限公司制药厂 | 6 | 4 | 0 |
| 9 | AbbVie Inc. | 6 | 2 | 0 |
| 10 | Eli Lilly Italia S.p.A. | 6 | 1 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Compared across this platform's snapshots of the under-review list
Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.
DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers no longer on the under-review list whose last snapshot sighting falls in this week, meaning approved or terminated, to be verified. Companies are counted by first applicant.
Class 3 and new-drug acceptances
137 this week
107 more not listed (at most 30 rows).
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.